Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Zealand Pharma A/S
Headquarters: Glostrup, Denmark
Website: http://www.zealandpharma.com...
Year Founded: 1998
Status: Public
Industry Sector: HealthTechnology
CEO: Adam Sinding Steensberg, MD, MBA
Number Of Employees: 335
Enterprise Value: $5,545,849,333
PE Ratio: -28.47
Exchange/Ticker 1: CSE:ZEAL
Exchange/Ticker 2: N/A
Latest Market Cap: $4,815,071,185
BioCentury | Mar 24, 2025
Data Byte
Petrelintide up front shatters biotech deal record
At nearly $1.7B, Zealand got $300M more than the prior top cash payment
BioCentury | Mar 17, 2025
Deals
AZ acquires cell therapy play Esobiotech, Taiho acquires ADC partner Araris: Deals Report
Plus: Roche partners with Zealand, AZ with Alteogen and more
BioCentury | Mar 12, 2025
Deals
Chasing amylin: Must-have obesity target key to Roche-Zealand deal
Swiss pharma pays $1.7B upfront for Zealand’s petrelintide, adding obesity’s hottest target
BioCentury | Mar 3, 2025
Deals
Abbvie joins obesity race with Gubra amylin deal
Does the deal signal additional support for amylin monotherapy, or suggest the pharma may soon make deals for complementary mechanisms?
BioCentury | Dec 31, 2024
Finance
Biotech raises make 2024 the year of the PIPE
BioCentury’s final Public Equity Report of the year tallies up fundraising activity
BioCentury | Dec 20, 2024
Product Development
Novo’s market cap slims down on CagriSema obesity data
Placebo-adjusted weight loss falls short of 25%+ expectations, doesn’t differentiate from Lilly’s Zepbound
BioCentury | Dec 17, 2024
Product Development
Obesity newcos aim for differentiation
New targets start to outnumber incretins among start-ups exploring paths to deeper, higher-quality weight loss
BioCentury | Dec 4, 2024
Data Byte
Nine PDUFA dates on FDA’s December calendar
Ionis’ first wholly owned product among three rare disease therapies up for approval. BMS expecting decision on subcutaneous Opdivo
BioCentury | Nov 15, 2024
Product Development
Pharmas challenging Novo and Lilly in obesity
An analysis of which major pharmas are in, out, or still deciding whether to take on obesity heavyweights Eli Lilly and Novo Nordisk
BioCentury | Oct 1, 2024
Data Byte
Five PDUFA dates on FDA’s October agenda
Decisions include Opdivo as perioperative therapy for NSCLC, and a Lumakras combination for mCRC
Items per page:
1 - 10 of 294